1 citations
,
January 2013 in “Annals of Dermatology” Naproxen effectively treated a girl's eosinophilic pustular folliculitis when other treatments failed.
1 citations
,
October 2024 in “QJM” IL-12/23 inhibitors are more effective and have fewer common side effects than anti-TNF alpha for treating psoriasis.
1 citations
,
September 2025 in “Eye” Certain drugs can cause eyelid inflammation, so doctors should monitor and educate patients on eyelid care.
April 2026 in “Frontiers in Medicine” Upadacitinib effectively treats psoriasis and lichen planus together.
2 citations
,
July 2007 in “Cancer biology & therapy” Bexxar is highly effective as a first treatment for non-Hodgkin's lymphoma, with most patients alive and many in remission after eight years.
December 2025 in “Pharmaceutics” EV-based drug delivery shows promise but faces challenges in standardization and scalability.
March 2024 in “EMBO molecular medicine” Antiviral drugs, especially daclatasvir, may be a new treatment for a rare skin disease, improving survival and reducing symptoms in mice.
20 citations
,
March 2023 in “American Journal of Clinical Dermatology” Baricitinib improved severe hair loss in adults over 52 weeks and was safe to use.
May 2023 in “Reactions Weekly” January 2013 in “Reactions Weekly” Naproxen can cause serious lung issues, but high-dose aspirin might be safer.
10 citations
,
May 2011 in “American Journal of Hematology” Vinblastine can help treat childhood ITP but may cause reversible side effects.
May 2026 in “Journal of Human Immunity” Ruxolitinib reduced inflammation and improved symptoms in APECED patients but may cause anemia and weight gain.
April 2026 in “Clinical Journal of Gastroenterology” Upadacitinib can cause hypersensitivity that worsens ulcerative colitis symptoms.
35 citations
,
March 2010 in “Journal of Dermatological Science” Ebastine may help regrow hair in alopecia areata patients.
August 2024 in “JAMA Dermatology” Continuous baricitinib is needed to keep hair regrowth in severe alopecia areata.
1 citations
,
August 2021 in “Journal of Investigative Dermatology” ASLAN004 was safe and well-tolerated, supporting further development for treating certain diseases.
October 2022 in “Amplla Editora eBooks” Tocilizumab might be an effective treatment for COVID-19.
Anifrolumab improves quality of life and reduces steroid use in lupus patients.
Bempikibart may help regrow hair in people with alopecia areata.
8 citations
,
January 2023 in “Indian Dermatology Online Journal” Baricitinib effectively treats certain skin conditions but may have serious side effects.
3 citations
,
January 2025 in “Journal of Natural Products” Calancardin B may help reduce inflammation in immune cells.
June 2026 in “Journal of health economics and outcomes research” Ritlecitinib is more effective and cheaper than baricitinib for treating severe alopecia areata.
1 citations
,
April 2024 in “Clinical Medicine” Timely diagnosis and aggressive treatment with high-dose steroids and B-cell depletion therapies are effective for severe acute cutaneous lupus.
January 2021 in “Anais do Congresso Brasileiro de Reumatologia 2020” Tofacitinib improved arthritis and partially improved hair loss in a lupus patient without side effects.
5 citations
,
January 2022 in “Asian Journal of Pharmaceutical and Clinical Research” Emulgels are effective for delivering skin medications and cosmetics due to their easy application and controlled release.
9 citations
,
March 2008 in “British Journal of Dermatology” Efalizumab can cause unexpected excessive hair growth.
176 citations
,
June 2016 in “PLoS ONE” Nucleic acid polymers can enhance antiviral responses and improve treatment outcomes for chronic hepatitis B.
May 2026 in “Frontiers in Immunology” Bimekizumab effectively treats scalp cellulitis and improves quality of life.
2 citations
,
February 2018 in “InTech eBooks” TNF-alpha inhibitors can cause various immune-related skin issues.